Friday, 23 Aug 2019

You are here

FDA Enforces New Drug Safety Labeling for Pregnant Women

The traditional FDA pregnancy risk categories (A, B, C, D, X) have been scrapped in favor of a new labeling mandate called the pregnancy and lactation labeling rule (PLLR). This change has been under consideration at the FDA for nearly 2 years and was brought about by the belief that the old A-X labels were “confusing and overly simplistic”, did not adequately portray risk differences and tended to minimize discussion between physician and patient about the risks if taken during pregnancy or lactation.

The FDA undertook this change to “to include relevant clinical information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy and/or lactation.”  The new labeling will fall under sections 8.1-8.3 of the package insert and will contain info on the drug risk summary, clinical considerations and available data, including information regarding pregnancy registries for that product.  Section 8.2 must contain information on breast feeding, drug in breast milk drug levels and the effects of the drug on the infant. Lastly, section 8.3 will have data on pregnancy testing, recommendations on contraception and infertility information.

The new rule, which went into effect on 12/14/14, has adopted the requirement for the above narratives and data to more adequately portray maternal-fetal risks to assist patient-physician communication on these matters. The PLLR will require physicians to read more if they wish to know more on drugs and pregnancy.
-- Jack Cush, MD

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

NSAIDs Mediate Cardiovascular Risk in OA

NSAIDs have been linked to an increased risk of cardiovascular disease, but does this also hold for osteoarthritis (OA) patients.

Tofacitinib Gets a New Boxed Warning for Blood Clots and Death with Higher Doses

The U.S. Food and Drug Administration has approved new warnings about an increased risk of blood clots and of death with the 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR), which is used in patients with ulcerative colitis. 

EHR-Related Adverse Events Usually Involve Medications

Concerns about the unintended risks inherent in electronic health records (EHR) by analysis of EHR–related harms identified from large database of malpractice suits and claims; they found that EHR related adverse events exist, and may be associated with an severe harms and uncommonly, death.

Methotrexate Use Not Linked to Interstitial Lung Disease in RA

People with rheumatoid arthritis have a significant risk of developing interstitial lung disease (RA-ILD), yet there is often a question as to whether methotrexate (MTX) exposure can cause or worsen ILD.  A controlled cohort study suggests that MTX use is not associated with an increased risk of RA-ILD and instead, there is evidence suggesting MTX use may delay the onset of ILD.

FDA Adds Boxed Warning to Sleep Drugs

The Food and Drug Administration (FDA) added a Boxed Warning to several sleep medications (e.g., eszopiclone, zaleplon, and zolpidem), warning rare but serious injuries may occur as a result of abnormal sleep behaviors (sleepwalking, sleep driving, and engaging in other activities while not fully awake) when taking sleep medications. These complex sleep behaviors have also resulted in deaths.